Testosterone Cypionate Non-Responder Profile: Who Doesn't Respond and Why

Does Testosterone Cypionate Work for Everyone?

No. Testosterone cypionate raises serum testosterone in virtually all patients who receive adequate doses, but symptom resolution is a different matter entirely. A 2020 systematic review in the Journal of Clinical Endocrinology and Metabolism found that subjective improvements in libido, energy, and mood varied widely even when total testosterone normalized, pointing to receptor-level and co-morbidity factors that serum T alone cannot predict [1].

The distinction matters clinically. A man whose injection is "working" by lab criteria but who still feels fatigued and has low libido is not a treatment failure in the pharmacokinetic sense. He may be a non-responder in the symptomatic sense, and those two categories require completely different corrective actions.

What the Pharmaceutical Label Actually Promises

The FDA-approved labeling for testosterone cypionate injection (100 mg/mL and 200 mg/mL) specifies the drug for males with primary hypogonadism or hypogonadotropic hypogonadism confirmed by laboratory findings [2]. The label does not guarantee symptom resolution. It guarantees a pharmacological effect: elevation of serum testosterone into the eugonadal range. Patients and prescribers sometimes conflate those two outcomes.

Real-World Data from Patient Forums

On Reddit threads such as r/Testosterone and r/trt (communities with a combined 400,000+ members as of early 2025), the most recurrent complaint among self-described non-responders is "my numbers look good but I still feel terrible." This mirrors findings in the Travison et al. Analysis, which showed that the relationship between serum testosterone and symptom severity is non-linear, with the steepest symptom improvements occurring at the lower end of the normal range rather than scaling linearly upward [3].

The Five Root Causes of Non-Response

1. SHBG-Driven Free Testosterone Suppression

Sex hormone-binding globulin (SHBG) binds testosterone tightly, leaving only a small free fraction bioavailable to tissues. Men with high SHBG can have total testosterone at 700 to 800 ng/dL yet free testosterone well below 50 pg/mL, the lower bound suggested by the Endocrine Society's 2018 Clinical Practice Guideline [4].

Conditions that raise SHBG include hyperthyroidism, hepatitis, aging past 60, and regular use of certain anticonvulsants. In these patients, standard testosterone cypionate dosing raises total T but may not proportionally raise free T. The fix is not always a higher dose. Sometimes it is addressing the SHBG driver directly, switching to more frequent smaller injections to sustain a higher peak-to-trough ratio, or adding a low-dose oral DHEA adjunct under medical supervision.

2. Androgen Receptor Sensitivity Variants

The androgen receptor gene contains a polymorphic CAG repeat sequence in exon 1. Shorter repeats (fewer than 22 CAGs) correlate with higher receptor transactivation; longer repeats (more than 26 CAGs) correlate with reduced receptor sensitivity [5]. A man with a long CAG repeat may need higher free testosterone to achieve the same intracellular signaling that a man with a short repeat achieves at a much lower free T level.

This genetic reality is rarely tested in clinical practice, but it explains a subset of men who respond poorly to TRT across all formulations, not just testosterone cypionate. The NIH-funded study by Zitzmann et al. (N=90) found that CAG repeat length independently predicted symptom response to testosterone replacement after controlling for serum testosterone levels [5].

3. Elevated Estradiol and the Aromatase Problem

Testosterone cypionate is a substrate for aromatase, the enzyme encoded by the CYP19A1 gene that converts androgens to estrogens. Adipose tissue is the primary site of peripheral aromatization. Men with a body mass index above 30 kg/m² can convert enough testosterone to estradiol that net androgenic signaling is blunted, and symptoms of relative estrogen excess (water retention, mood instability, reduced libido) may emerge [6].

The EMAS (European Male Ageing Study, N=3,369) confirmed a U-shaped relationship between estradiol and sexual function in men: both very low and very high estradiol correlated with worse outcomes [7]. An estradiol target of 20 to 30 pg/mL is commonly cited in TRT management literature, though the Endocrine Society guideline notes that routine anastrozole use is not supported for most TRT patients [4].

Non-responders with high estradiol often report that weight loss of 10 to 15% body weight improves symptoms more than dose escalation does.

4. Downstream Hormonal Imbalances

Testosterone does not operate in isolation. Thyroid dysfunction, elevated prolactin, insulin resistance, and vitamin D deficiency each suppress androgen sensitivity or blunt tissue response independently of serum testosterone. A 2019 cross-sectional study in Andrology (N=2,120) found that men with subclinical hypothyroidism had significantly lower free testosterone and worse TRT outcomes compared with euthyroid controls, even when total testosterone was matched [8].

Prolactin is worth particular attention. Prolactinomas are rare but not negligible: the prevalence is approximately 10 per 100,000 men, and moderately elevated prolactin (40 to 100 ng/mL) suppresses GnRH pulsatility in ways that blunt response to exogenous testosterone at the tissue level [9].

5. Obstructive Sleep Apnea

Obstructive sleep apnea (OSA) suppresses nocturnal testosterone pulses driven by LH during slow-wave sleep. While exogenous testosterone cypionate bypasses this axis, OSA also independently suppresses androgen receptor expression in peripheral tissues through chronic intermittent hypoxia pathways. A meta-analysis in Sleep Medicine Reviews (9 studies, N=1,072) found that CPAP treatment raised morning testosterone by a mean of 72 ng/dL without any exogenous androgen [10].

Men on TRT with untreated OSA frequently report incomplete symptom resolution. Treating the OSA first, or concurrently, often converts a non-responder into a responder.

Protocol Errors That Mimic Non-Response

Not every apparent non-response reflects a true biological refractory state. Several common protocol errors create lab-confirmed normal T alongside persistent symptoms.

Injection Timing and the Peak-Trough Problem

Testosterone cypionate has a half-life of approximately 8 days [2]. On a standard every-14-day schedule, serum testosterone peaks at roughly day 2 to 4 post-injection and troughs at or below the normal range by day 12 to 14. A patient who has labs drawn at trough may show a low result, while a patient who subjectively self-assesses at trough feels hypogonadal for 4 to 6 days per cycle.

The T Trials (a set of seven placebo-controlled trials in men 65 and older, sponsored by the NIH) demonstrated that symptom consistency tracked better with time-averaged testosterone than with single peak measurements [11]. Moving from biweekly to weekly injections of the same total monthly dose (e.g., 100 mg/week instead of 200 mg/every 2 weeks) substantially flattens the peak-trough fluctuation and resolves trough-related symptoms in a subset of apparent non-responders.

Injection Technique

Subcutaneous vs. Intramuscular administration alters pharmacokinetics. A study in Journal of Clinical Endocrinology and Metabolism (N=28) found that subcutaneous testosterone cypionate at the same dose produced lower but more stable peak testosterone levels with reduced estradiol conversion compared with IM administration [12]. Some patients switch routes without realizing this and interpret the lower peak as treatment failure when it may actually represent a more favorable steady-state profile.

Monitoring at the Wrong Interval

The Endocrine Society recommends checking serum testosterone 3 to 6 months after initiating therapy or adjusting dose, not at 4 to 6 weeks [4]. Early labs capture neither the steady state nor the full tissue-level adaptation. Patients who self-assess at 6 weeks and declare failure are almost always assessing too early.

Laboratory Workup for the TRT Non-Responder

A structured second-look panel for men failing to respond symptomatically should include the following:

| Test | Target Range | Why It Matters | |---|---|---| | Total testosterone (trough) | 400 to 700 ng/dL | Confirm delivery adequacy | | Free testosterone (calculated or equilibrium dialysis) | 50 to 150 pg/mL | Identify SHBG suppression | | SHBG | 20 to 50 nmol/L | Quantify binding burden | | Estradiol (sensitive LC-MS/MS assay) | 20 to 30 pg/mL | Rule out aromatase excess | | LH/FSH | Suppressed on exogenous T (expected) | Confirm compliance; rule out non-injection | | Prolactin | <20 ng/mL | Rule out microadenoma | | TSH, free T4 | TSH 0.5 to 2.5 mIU/L | Rule out thyroid interference | | Fasting insulin, HbA1c | Normal range | Assess insulin resistance | | Vitamin D (25-OH) | 40 to 60 ng/mL | Rule out deficiency | | CBC, hematocrit | <54% | Safety monitoring per FDA label |

The FDA label for testosterone cypionate specifically requires hematocrit monitoring due to erythrocytosis risk [2]. Polycythemia can itself worsen fatigue and cognitive symptoms, ironically mimicking hypogonadal complaints.

What Patients Report: Synthesizing Real-World Experience

Reddit and Forum Patterns

Across r/trt, r/Testosterone, and Drugs.com review threads, non-responder accounts cluster into three narrative types:

1. "My T is 700 but I feel the same as when it was 250." These patients almost uniformly have either high SHBG, high estradiol, or an undiagnosed co-morbidity.
2. "I felt great for 3 months then it stopped working." This pattern often reflects adaptation of the HPG axis feedback, changes in SHBG over time, or a lifestyle factor (weight gain, worsening sleep) that emerged after initiation.
3. "I never felt anything at all, ever." This group has the highest rate of androgen receptor insensitivity variants and secondary diagnoses like undiagnosed OSA or celiac disease with micronutrient malabsorption.

These experiential patterns align with clinical literature. The Bhasin et al. Dose-response study (N=61) showed that while lean mass increased dose-dependently, sexual function and energy responses had a much flatter dose-response curve, suggesting a ceiling effect governed by receptor sensitivity rather than serum hormone level [13].

When Testosterone Cypionate Genuinely Does Not Work

A small subset of men, likely under 5% of TRT initiates, have androgen insensitivity spectrum conditions that are incomplete and partial rather than complete. Partial androgen insensitivity syndrome (PAIS) may present as adult males with apparently normal anatomy but blunted androgenic response. Genetic testing (AR gene sequencing) can identify pathogenic variants [14].

Outside of frank genetic insensitivity, true pharmacological non-response to testosterone cypionate specifically (as opposed to other formulations) is rare. The molecule delivers testosterone identically to testosterone enanthate with a slightly longer half-life. A man who responds poorly to cypionate but not to propionate is almost always experiencing a vehicle tolerability issue rather than a fundamental hormonal block.

Clinical Protocol for Converting Non-Responders

The Endocrine Society's guideline states: "We suggest that clinicians evaluate the adequacy of testosterone therapy by measuring serum testosterone levels and assessing symptom improvement 3 to 6 months after starting treatment" [4]. That guideline further specifies checking hematocrit, PSA, and cardiovascular risk at each follow-up.

A systematic approach to the non-responder follows four steps:

Step 1. Verify pharmacokinetic adequacy. Draw trough testosterone (immediately before the next scheduled injection) and free testosterone. If trough total T is below 400 ng/dL or free T is below 50 pg/mL, the dose or interval needs adjustment before any other intervention.

Step 2. Rule out the five root causes above with the laboratory panel in the table. Correct each identified abnormality before escalating testosterone dose.

Step 3. Optimize injection frequency. If the patient is on a 14-day schedule, trial a 7-day schedule at the same total weekly dose for 12 weeks and repeat symptom scoring with a validated instrument such as the Androgen Deficiency in Aging Males (ADAM) questionnaire or the International Index of Erectile Function (IIEF).

Step 4. Reassess the original diagnosis. If symptoms persist after steps 1 to 3, revisit whether hypogonadism was the correct primary diagnosis. Depression, generalized anxiety disorder, and chronic fatigue syndrome each overlap substantially with hypogonadal symptom profiles. The T Trials showed that sexual function improvements were strong but that vitality improvements were modest and not significantly different from placebo in men whose baseline symptoms were primarily fatigue-driven [11].

Special Populations With Higher Non-Response Rates

Men Over 65

Older men have higher baseline SHBG, greater aromatase activity per unit fat mass, and lower androgen receptor density in muscle tissue. The T Trials (N=790 men, mean age 72) showed that testosterone therapy improved sexual activity and desire by modest but statistically significant margins, yet improvements in physical function and vitality were smaller and less consistent [11]. Non-response rates in this cohort are higher than in younger men with classical hypogonadism.

Men With Type 2 Diabetes

Insulin resistance suppresses SHBG and alters androgen receptor phosphorylation. A prospective study in Diabetes Care (N=857) found that men with T2DM had lower free testosterone responses to exogenous testosterone than non-diabetic controls matched for total T, suggesting impaired receptor-level signaling in the setting of metabolic dysfunction [15]. Glycemic optimization before or alongside TRT initiation improves response rates in this population.

Men With Prior Anabolic Steroid Use

Long-term supraphysiologic androgen exposure from anabolic steroids downregulates androgen receptor density and can cause prolonged HPG axis suppression. Men with this history who then begin therapeutic testosterone cypionate may have a blunted tissue-level response even at normal serum levels. Recovery of receptor sensitivity may take 12 to 24 months of consistent physiologic testosterone exposure [16].